References
- Dierks C, Grbic J, Zirlik K, et al. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944–51
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
- Ingham PW, McMahon AP. (2001). Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059–87
- Irvine DA, Copland M. (2012). Targeting hedgehog in hematologic malignancy. Blood 119:2196–204
- Martinelli G, Oehler VG, Papayannidis C, et al. (2015). Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol 2:e339–46
- McMillan R, Matsui W. (2012). Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res 18:4883–8
- Munchhof MJ, Li Q, Shavnya A, et al. (2012). Discovery of PF-04449913, a potent and orally bioavailable inhibitor of Smoothened. ACS Med Chem Lett 3:106–11
- Peacock CD, Wang Q, Gesell GS, et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 104:4048–53
- Robison TW, Jacobs A. (2009). Metabolites in safety testing. Bioanalysis 1:1193–200
- Shaik MN, Labadie RR, Rudin D, Levin WJ. (2014). Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemother Pharmacol 74:411–8
- Wagner AJ, Messersmith WA, Shaik MN, et al. (2015). A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21:1044–51
- Yang X, Atkinson K, Di L. (2016). Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab Dispos 44:460–5
- Zhao C, Chen A, Jamieson CH, et al. (2009). Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458:776–9